Genelux

• Home
• About
  1. Board of Directors
  2. Management Team
  3. Advisory Boards
• Technology
  1. Science Division
  2. Therapy
  3. Imaging
• Products
  1. GL-ONC1
  2. Future Products
• Clinical Trials
  1. Clinical Trials Operations
  2. About Clinical Trials
• Patents & Publications
  1. Scientific Publications
  2. Intellectual Property
• News & Events
  1. Press Releases
  2. In The News
  3. Events & Conferences
  4. Media Relations Contact
• Investor Relations
• Careers
• Contact

Clinical Trials

The company’s first-in-man Phase I clinical trial of GL-ONC1 has been completed and final results are expected soon. An additional Phase I/II trial is set to begin imminently exploring cancers of the Peritoneal Cavity. Further clinical trials are in regulatory preparation and/or submission stages.

Please note that any information regarding patient selection and participation in any clinical trial involving Genelux products will be available only from the clinical institutions conducting the trial. Study summaries and patient selection criteria for clinical trials associated with Genelux Corporation will be posted on www.clinicaltrials.gov, the public registry managed by the National Institutes of Health.